Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Perdomo

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Obesity Science & Practice|July 6, 2019
Effect of lorcaserin on weight reduction in persons with obstructive sleep apnea (OSA): a combined subgroup analysis from three randomized, controlled clinical trialsK Fujioka, C Perdomo, M Malhotra
International Journal of Geriatric Psychiatry|January 3, 2007
Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's diseaseA Burns, S Gauthier, C Perdomo
Domestic Animal Endocrinology|July 30, 2011
Trans-10, cis-12 conjugated linoleic acid and the PPAR-γ agonist rosiglitazone attenuate lipopolysaccharide-induced TNF-α production by bovine immune cellsM C Perdomo, J E Santos, L Badinga
European Journal of Gastroenterology & Hepatology|August 10, 2000
The benefit/risk profile of rabeprazole, a new proton-pump inhibitorD Johnson, C Perdomo, J Barth, et al.
Alimentary Pharmacology & Therapeutics|August 11, 2005
Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United StatesA Caos, J Breiter, C Perdomo, et al.
European Journal of Gastroenterology & Hepatology|August 25, 2000
Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study GroupC Birbara, J Breiter, C Perdomo, et al.
Obesity Science & Practice|April 26, 2019
Effect of lorcaserin in different age groups: a post hoc analysis of patients from the BLOOM, BLOSSOM and BLOOM-DM studiesK Fujioka, M Malhotra, C Perdomo, et al.
Diabetes, Obesity & Metabolism|May 14, 2016
Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studiesC Apovian, K Palmer, R Fain, et al.
Obesity Science & Practice|December 22, 2018
Lorcaserin and metabolic disease: weight-loss dependent and independent effectsH Bays, C Perdomo, E Nikonova, et al.
Water Science and Technology : a Journal of the International Association on Water Pollution Research|August 24, 2005
Evaluation of sludge from pond system for treatment of piggery wastesC T Zanotelli, R H R Costa, C C Perdomo
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Obesity Science & Practice|July 6, 2019
Effect of lorcaserin on weight reduction in persons with obstructive sleep apnea (OSA): a combined subgroup analysis from three randomized, controlled clinical trialsK Fujioka, C Perdomo, M Malhotra
International Journal of Geriatric Psychiatry|January 3, 2007
Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's diseaseA Burns, S Gauthier, C Perdomo
Domestic Animal Endocrinology|July 30, 2011
Trans-10, cis-12 conjugated linoleic acid and the PPAR-γ agonist rosiglitazone attenuate lipopolysaccharide-induced TNF-α production by bovine immune cellsM C Perdomo, J E Santos, L Badinga
European Journal of Gastroenterology & Hepatology|August 10, 2000
The benefit/risk profile of rabeprazole, a new proton-pump inhibitorD Johnson, C Perdomo, J Barth, et al.
Alimentary Pharmacology & Therapeutics|August 11, 2005
Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United StatesA Caos, J Breiter, C Perdomo, et al.
European Journal of Gastroenterology & Hepatology|August 25, 2000
Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study GroupC Birbara, J Breiter, C Perdomo, et al.
Obesity Science & Practice|April 26, 2019
Effect of lorcaserin in different age groups: a post hoc analysis of patients from the BLOOM, BLOSSOM and BLOOM-DM studiesK Fujioka, M Malhotra, C Perdomo, et al.
Diabetes, Obesity & Metabolism|May 14, 2016
Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studiesC Apovian, K Palmer, R Fain, et al.
Obesity Science & Practice|December 22, 2018
Lorcaserin and metabolic disease: weight-loss dependent and independent effectsH Bays, C Perdomo, E Nikonova, et al.
Water Science and Technology : a Journal of the International Association on Water Pollution Research|August 24, 2005
Evaluation of sludge from pond system for treatment of piggery wastesC T Zanotelli, R H R Costa, C C Perdomo
Pageof 5